« Return to News | Study Conduct

Kenexa partners with Eli Lilly

Thursday, November 17, 2011 03:08 PM

Kenexa, a global provider of business solutions for human resources, has reported that Eli Lilly will be using Kenexa’s global recruitment process outsourcing (RPO) services in some of the major markets where Lilly conducts business globally. The five year engagement represents Kenexa’s largest global RPO partnership, and also includes Kenexa’s onboarding, recruiting, assessment, and survey solutions and employment branding.  

Lilly sought to consolidate many of its global recruitment processes in order to increase efficiencies in the end-to-end recruiting process. Lilly and Kenexa share a strong presence in several global growth markets which further established synergies between the companies.

Rudy Karsan, CEO of Kenexa, commented, “Improving outcomes, enriching lives is the mantra of Kenexa’s relationship with Lilly. Kenexa is proud to be an integral part of Lilly’s global recruiting program.”

“Our selection process was rigorous and Kenexa met our expectations by showcasing their global RPO services capabilities and providing access to their centers of excellence in Asia, Europe, and the Americas,” said Nancy Lange, senior director for global recruiting and staffing for Lilly.  “The company demonstrated their strengths in integrating services, technology, and relevant content.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.